Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (321-330 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|September 17, 2016
Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trialTakeshi Kitai, Justin L Grodin, Robert J Mentz, et al.
Circulation|May 5, 2016
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
European Heart Journal|April 17, 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeMichael R MacDonald, Mark C Petrie, Fumi Varyani, et al.
American Heart Journal|April 29, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
JACC. Heart Failure|May 13, 2019
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HFCraig Balmforth, Joanne Simpson, Li Shen, et al.
Journal of the American College of Cardiology|November 18, 2017
Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection FractionUlrik M Mogensen, Pardeep S Jhund, William T Abraham, et al.
American Heart Journal|February 23, 2021
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trialsMuhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, et al.
American Journal of Therapeutics|July 17, 2010
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fractionNorman C Wang, Jonathan P Piccini, Marvin A Konstam, et al.
Pageof 48

Showing results (321-330 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|September 17, 2016
Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trialTakeshi Kitai, Justin L Grodin, Robert J Mentz, et al.
Circulation|May 5, 2016
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
Lancet (London, England)|July 11, 2003
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialPhilip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
European Heart Journal|April 17, 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeMichael R MacDonald, Mark C Petrie, Fumi Varyani, et al.
American Heart Journal|April 29, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
JACC. Heart Failure|May 13, 2019
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HFCraig Balmforth, Joanne Simpson, Li Shen, et al.
Journal of the American College of Cardiology|November 18, 2017
Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection FractionUlrik M Mogensen, Pardeep S Jhund, William T Abraham, et al.
American Heart Journal|February 23, 2021
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trialsMuhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, et al.
American Journal of Therapeutics|July 17, 2010
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fractionNorman C Wang, Jonathan P Piccini, Marvin A Konstam, et al.
Pageof 48